Last update 21 Mar 2024
HIVEP2
HIVEP zinc finger 2
Last update 21 Mar 2024
Basic Info
Synonyms HIV-EP2, HIVEP zinc finger 2, HIVEP2 + [8] |
Introduction This protein specifically binds to the DNA sequence 5'-GGGACTTTCC-3' which is found in the enhancer elements of numerous viral promoters such as those of SV40, CMV, or HIV1. In addition, related sequences are found in the enhancer elements of a number of cellular promoters, including those of the class I MHC, interleukin-2 receptor, somatostatin receptor II, and interferon-beta genes. It may act in T-cell activation. |
Related
100 Clinical Results associated with HIVEP2
Login to view more data
100 Translational Medicine associated with HIVEP2
Login to view more data
0 Patents (Medical) associated with HIVEP2
Login to view more data
101
Literatures (Medical) associated with HIVEP220 Dec 2023·European journal of human genetics : EJHG
De novo variants underlying monogenic syndromes with intellectual disability in a neurodevelopmental cohort from India.
Article
Author: Shruti Pande ; Purvi Majethia ; Karthik Nair ; Lakshmi Priya Rao ; Selinda Mascarenhas ; Namanpreet Kaur ; Michelle C do Rosario ; Kausthubham Neethukrishna ; Ankur Chaurasia ; Bhagesh Hunakunti ; Nalesh Jadhav ; Sruthy Xavier ; Jeevan Kumar ; Vivekananda Bhat ; Gandham SriLakshmi Bhavani ; Dhanya Lakshmi Narayanan ; B L Yatheesha ; Siddaramappa J Patil ; Sheela Nampoothiri ; Nutan Kamath ; Shrikiran Aroor ; Ramesh Bhat Y ; Leslie E Lewis ; Suvasini Sharma ; Shruti Bajaj ; Naveen Sankhyan ; Shahyan Siddiqui ; Shalini S Nayak ; Stephanie Bielas ; Katta Mohan Girisha ; Anju Shukla
The contribution of de novo variants as a cause of intellectual disability (ID) is well established in several cohorts reported from the developed world. However, the genetic landscape as well as the appropriate testing strategies for identification of de novo variants of these disorders remain largely unknown in low-and middle-income countries like India. In this study, we delineate the clinical and genotypic spectrum of 54 families (55 individuals) with syndromic ID harboring rare de novo variants. We also emphasize on the effectiveness of singleton exome sequencing as a valuable tool for diagnosing these disorders in resource limited settings. Overall, 46 distinct disorders were identified encompassing 46 genes with 51 single-nucleotide variants and/or indels and two copy-number variants. Pathogenic variants were identified in CREBBP, TSC2, KMT2D, MECP2, IDS, NIPBL, NSD1, RIT1, SOX10, BRWD3, FOXG1, BCL11A, KDM6B, KDM5C, SETD5, QRICH1, DCX, SMARCD1, ASXL1, ASXL3, AKT3, FBN2, TCF12, WASF1, BRAF, SMARCA4, SMARCA2, TUBG1, KMT2A, CTNNB1, DLG4, MEIS2, GATAD2B, FBXW7, ANKRD11, ARID1B, DYNC1H1, HIVEP2, NEXMIF, ZBTB18, SETD1B, DYRK1A, SRCAP, CASK, L1CAM, and KRAS. Twenty-four of these monogenic disorders have not been previously reported in the Indian population. Notably, 39 out of 53 (74%) disease-causing variants are novel. These variants were identified in the genes mainly encoding transcriptional and chromatin regulators, serine threonine kinases, lysosomal enzymes, molecular motors, synaptic proteins, neuronal migration machinery, adhesion molecules, structural proteins and signaling molecules.
07 Dec 2023·BMC microbiology
Gut dysbacteriosis induces expression differences in the adult head transcriptome of Spodoptera frugiperda in a sex-specific manner.
Article
Author: Junrui-Fu ; Zixia Rong ; Ximei Huang ; Junhan Wang ; Xiaoyan Long ; Qili Feng ; Huimin Deng
Mounting evidence indicates that the gut microbiota influences the neurodevelopment and behavior of insects through the gut-brain axis. However, it is currently unclear whether the gut microbiota affect the head profiles and immune pathway in pests. Here, we find that gut bacteria is essential for the immune and neural development of adult Spodoptera frugiperda, which is an extremely destructive agricultural pest worldwide. 16 S rRNA sequencing analysis showed that antibiotics exposure significantly disturbed the composition and diversity of gut bacteria. Further transcriptomic analysis revealed that the adult head transcripts were greatly affected by gut dysbacteriosis, and differently expression genes critical for brain and neural development including A4galt, Tret1, nsun4, Galt, Mitofilin, SLC2A3, snk, GABRB3, Oamb and SLC6A1 were substantially repressed. Interestingly, the dysbacteriosis caused sex-specific differences in immune response. The mRNA levels of pll (serine/threonine protein kinase Pelle), PGRP (peptidoglycan-sensing receptor), CECA (cecropin A) and CECB (cecropin B) involved in Toll and Imd signaling pathway were drastically decreased in treated male adults' heads but not in female adults; however, genes of HIVEP2, ZNF131, inducible zinc finger protein 1-like and zinc finger protein 99-like encoding zinc-finger antiviral protein (ZAP) involved in the interferon (IFNα/β) pathway were significantly inhibited in treated female adults' heads. Collectively, these results demonstrate that gut microbiota may regulate head transcription and impact the S. frugiperda adults' heads through the immune pathway in a sex-specific manner. Our finding highlights the relationship between the gut microbiota and head immune systems of S. frugiperda adults, which is an astonishing similarity with the discoveries of other animals. Therefore, this is the basis for further research to understand the interactions between hosts and microorganisms via the gut-brain axis in S. frugiperda and other insects.
06 Oct 2023·Medicine
Gastric cancer metastasis-related NT5DC2 indicates unfavorable prognosis of patients.
Article
Author: Rula Sha ; Jiaming Zhang ; Fanjie Meng ; Getu Zhaori
PURPOSE:
Approximately 80 to 90% of patients with gastric cancer (GC) eventually develop into metastatic GC nowadays,because GC is difficult to be diagnosed at an early stage. GC patients with metastases typically have a poor prognosis. It is necessary to explore a potential prognostic marker in metastatic GC.
METHODS:
All GC data were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. The metastasis-related candidate gene and its role in GC were analyzed by comprehensive analysis.
RESULTS:
Totally 1049 metastasis-related genes were identified in GC. Univariate Cox regression analysis screened the top 10 genes (PDHX, SLC43A1, CSAG2, NT5DC2, CSAG1, FMN1, MED1, HIVEP2, FNDC3A, and PPP1R2) that were closely correlated with prognosis of GC patients. Among which, NT5DC2 was screened as the target gene for subsequent study. The NT5DC2 expression were increased in primary GC and metastatic GC samples. Moreover, GC patients with high NT5DC2 expression exhibited shorter overall survival and post progression survival, and the NT5DC2 was metastatic GC patients' independent prognostic factor. Totally 29 pathways were activated in metastatic GC samples with high NT5DC2 expression. Four immune cells' infiltration were significantly different between NT5DC2 high and low expressed metastatic GC patients. NT5DC2 showed significantly negative correlations with 6 types of immune cells' critical marker genes and 5 types of immune cell infiltration. The 10 immune checkpoint expressions were decreased in high NTDC2 expression metastatic GC patients.
CONCLUSIONS:
NT5DC2 plays a prognostic role in metastatic GC. GC patients with high NT5DC2 expression indicates unfavorable prognosis.
2
News (Medical) associated with HIVEP202 Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of two poster presentations, including a late-breaking presentation on the company’s oral selective PPAR⍺ antagonist, TPST-1120, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 10-12, 2022 in Boston, MA.
Late-breaking poster presentation details:
Title:
Pharmacodynamic and predictive biomarkers associated with response in cancer patients treated with TPST-1120: a first-in-class, small molecule antagonist of Peroxisome-Proliferator Activated Receptor-Alpha
Abstract #:
1471
Date:
Thursday, November 10, 2022
Time:
9:00 a.m. – 9:00 p.m. ET
Location:
Poster Hall C
Poster presentation details:
Title:
Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway
Abstract #:
1331
Date:
Thursday, November 10, 2022
Time:
9:00 a.m. – 9:00 p.m. ET
Location:
Poster Hall C
Full abstracts will be available for viewing starting on Monday, November 7, 2022 at 8:00 a.m. ET in the Journal for ImmunoTherapy of Cancer (JITC) supplement found at .
——————————————
1 If approved by the FDA
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both programs are advancing through clinical trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at .
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
CollaborateFirst in ClassImmunotherapySmall molecular drug
06 Oct 2022
Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” SessionNicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company’s TREX1 pipeline asset and will serve as chairperson for the “New Approaches to Solid Tumor Targeting” session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA. TREX1 Presentation Dr. Burdette’s presentation will describe the company’s approach to identify and characterize novel small molecule inhibitors of the 3’-5’ DNA repair exonuclease, TREX1. TREX1 inhibits cGAS/STING signaling and is induced in tumor cells due to genetic instability or therapeutic intervention. Tempest’s program aims to generate an anti-tumor response through selectively activating the STING pathway in advanced metastatic cancers with orally available small molecule inhibitors of TREX1. Presentation details: Title:Small Molecules Targeting the 3’-5’ DNA Repair Exonuclease TREX1 SelectivelyActivate the STING Pathway and Induce Tumor-Specific ImmunityDate:Thursday, October 13, 2022Time:2:40 p.m. EDT TPST-1495 Presentation In addition, Nicholas DeVito, M.D., a medical oncologist and medical instructor in the laboratory of Dr. Brent Hanks, M.D., Ph.D. at Duke University School of Medicine, will be giving a presentation describing pre-clinical results with TPST-1495, Tempest’s clinical-stage dual inhibitor of the EP2 and EP4 prostaglandin E2 receptors, in mice bearing tumors with designated gene expression profiles. Presentation details: Title:Understanding Tumor-Mediated Immune Evasion to Develop Biomarkers toward Rational Therapeutic CombinationsDate:Wednesday, October 12, 2022Time:8:40 a.m. EDT About Tempest Therapeutics Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both programs are advancing through clinical trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com. Investor Contacts:Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@wheelhouselsa.com 1 If approved by the FDA
CollaborateFirst in ClassSmall molecular drug
Analysis
Perform a panoramic analysis of this field.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free